Zacks Investment Research Downgrades Medicure Inc. (MCUJF) to Hold

Medicure Inc. (OTCMKTS:MCUJF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Medicure Inc is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine. In addition to MC-4232, they are also conducting Phase II clinical trials with MC-1, which is focused on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke. “

Separately, ValuEngine raised shares of Medicure from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th.

Shares of Medicure (OTCMKTS MCUJF) opened at 6.6196 on Wednesday. The firm has a market cap of $103.48 million, a price-to-earnings ratio of 5.8893 and a beta of 0.56. The stock has a 50 day moving average of $6.41 and a 200 day moving average of $6.19. Medicure has a 52-week low of $4.11 and a 52-week high of $7.96.

COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Downgrades Medicure Inc. (MCUJF) to Hold” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2956301/zacks-investment-research-downgrades-medicure-inc-mcujf-to-hold.html.

Medicure Company Profile

Medicure Inc (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS).

Receive News & Ratings for Medicure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.